Source:http://linkedlifedata.com/resource/pubmed/id/20563590
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2010-11-1
|
| pubmed:abstractText |
The objective of the study was to evaluate patient benefit and health-related quality of life after use of botulinum neurotoxin (BoNT) A for various otorhinolaryngological, functional (non-cosmetic) indications. The design consisted of a survey study of a patient cohort (n = 40) treated with BoNT A for functional indications. Patients were asked to answer the Glasgow Benefit Inventory (GBI), a retrospective questionnaire well validated for measuring the effect of otorhinolaryngological interventions on the health-related quality of life. GBI scores can range from -100 (maximal adverse effect), through 0 (no effect), to 100 (maximal positive effect). A total of 29 patients (72.5%) returned a valid questionnaire. Mean total GBI scores for the particular indications were 1.2 (sialorrhea, n = 7), 22.6 (gustatory sweating, n = 8), 20.6 (palatal tremor, n = 5), 15.0 (postlaryngectomy voice disorders due to pharyngoesophageal spasm, n = 5), 38.9 (adductor spasmodic dysphonia, n = 2) and 27.8 (oromandibular dystonia, n = 2), showing a mean overall positive effect of BoNT A treatment on the health-related quality of life, respectively. A varying percentage of patients reported an increase in their health-related quality of life, indicated by positive total GBI scores: sialorrhea 28.6%, gustatory sweating 87.5%, palatal tremor 60%, postlaryngectomy voice disorders 60%, spasmodic dysphonia 100% and oromandibular dystonia 100%. Use of BoNT A can be considered an effective therapeutic option for all the indications investigated. However, the possibility of raising patients' health-related quality of life with this kind of therapy varies significantly for different indications. Further studies are needed to analyze the patients who will benefit most from a treatment with BoNT A.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1434-4726
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
267
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1963-7
|
| pubmed:meshHeading |
pubmed-meshheading:20563590-Adolescent,
pubmed-meshheading:20563590-Adult,
pubmed-meshheading:20563590-Aged,
pubmed-meshheading:20563590-Aged, 80 and over,
pubmed-meshheading:20563590-Botulinum Toxins, Type A,
pubmed-meshheading:20563590-Child,
pubmed-meshheading:20563590-Cohort Studies,
pubmed-meshheading:20563590-Female,
pubmed-meshheading:20563590-Health Status,
pubmed-meshheading:20563590-Humans,
pubmed-meshheading:20563590-Male,
pubmed-meshheading:20563590-Middle Aged,
pubmed-meshheading:20563590-Neuromuscular Agents,
pubmed-meshheading:20563590-Palatal Muscles,
pubmed-meshheading:20563590-Quality of Life,
pubmed-meshheading:20563590-Retrospective Studies,
pubmed-meshheading:20563590-Sialorrhea,
pubmed-meshheading:20563590-Sweating, Gustatory,
pubmed-meshheading:20563590-Treatment Outcome,
pubmed-meshheading:20563590-Tremor,
pubmed-meshheading:20563590-Voice Disorders,
pubmed-meshheading:20563590-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Patient benefit from treatment with botulinum neurotoxin A for functional indications in otorhinolaryngology.
|
| pubmed:affiliation |
Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig Maximilian University, Marchioninistrasse 15, 81377, Munich, Germany. thomas.braun@med.uni-muenchen.de
|
| pubmed:publicationType |
Journal Article
|